Patients with gain-of-function mutations in NLRC4 can be clinically characterized by early-onset, recurrent MAS and inflammatory bowel disease, and very high IL-18 levels similar to those in patients with MAS associated with s-JIA and AOSD (8, 33). This evidence concerns the gene NLRC4 and macrophage activation syndrome.